Αποτελέσματα Αναζήτησης
28 Αυγ 2020 · Milrinone is a medication indicated for cardiac support in patients with acute heart failure, pulmonary hypertension, or chronic heart failure. It improves cardiac contractility (inotropy) and cardiac relaxation (lusitropy) and induces vasodilation.
Milrinone is a PDE-III inhibitor with inotropic, lusitropic, and vasodilatory properties used for the short-term treatment of acute decompensated heart failure. Generic Name. Milrinone. DrugBank Accession Number. DB00235. Background. Heart failure is a multifactorial condition that affects roughly 1-2% of the adult population.
In this article, we review the pharmacology and discuss the use of this agent in both the acutely decompensated CHF patient and also in the management of patients with advanced, end-stage CHF for improvement in quality of life and decreased hospitalization.
26 Δεκ 2019 · Milrinone infusion is one of a few select “non-device” therapies for patients with New York Heart Association (NYHA) class IV, stage D heart failure, which has been associated with an increase in ventricular tachyarrhythmia and atrial fibrillation. Milrinone improves hemodynamics and provides symptomatic relief.
7 Ιουλ 2020 · The Mil HFPEF (Extended Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction) study was a randomized, double‐blind, placebo‐controlled pilot study in 23 patients with symptomatic HF p EF.
Milrinone inhibits phosphodiesterase 3 in cardiac and smooth muscle tissues, thus increasing cyclic adenosine monophosphate levels and a resultant increase in intracellular ionised calcium. It is a positive inotrope and a systemic and pulmonary arterial vasodilator, with little positive chronotropic effect.
Milrinone (Inocor-Sanofi-Winthrop) represents a second generation phosphodiesterase inhibitor currently approved for intravenous administration in the treatment of decompensated congestive heart failure.
